14 results

• FDA Puts New Stomach Cancer Restrictions in Place for Keytruda, Opdivo

  June 10, 2025

  Irvin Jackson

  Federal regulators have sent letters to Merck and Bristol-Myers Squibb, announcing new restrictions on the use of Keytruda and Opdivo for the treatment of stomach cancer.

• Keytruda, Similar Cancer Drugs May Increase Risk of Pulmonary Embolism: Study

  October 17, 2024

  Martha Garcia

  New research indicates the use of certain cancer treatment drugs, like Keytruda and Opdivo, could pose a high risk of life-threatening cardiovascular events, adding to recent concerns about the class of medications.

• FDA Advisors Vote for Restrictions on Opdivo, Keytruda, Similar Stomach Cancer Drugs

  September 30, 2024

  Irvin Jackson

  Independent scientific advisory board is calling for restrictions on stomach cancer drugs like Keytruda and Opdivo, saying they do little to extend the lives of certain cancer patients.

• Merck Halts Keytruda Cancer Trials Due to Reported Adverse Events, Including One Patient Death

  August 30, 2024

  Martha Garcia

  Two clinical trials involving the cancer drug Keytruda have been halted, after it failed to show promise in treating certain types of lung and skin cancer, and increased the risk of adverse events, which led to the death of at least one patient.

• FDA Advisors Set to Consider Stomach Cancer Restrictions for Yervoy, Opdivo, Keytruda

  August 23, 2024

  Irvin Jackson

  An FDA advisory committee has been asked to determine if there should be restrictions on the use of some popular cancer drugs, like Opdivo and Keytruda, for the treatment of stomach cancer, following years of concerns about the drugs' safety risks.

• Case Study Links Keytruda to Severe Immune-Related Enteritis After Pregnancy Exposure

  November 20, 2023

  Katherine McDaniel

  A new case study links Keytruda exposure in the womb to a risk of severe enteritis in newborns.

• Only One-Fifth Of Cancer Drugs Approved Through Accelerated FDA Program Actually Work: Study

  May 31, 2019

  Martha Garcia

  Most cancer drugs fast-tracked through a special FDA program do not appear to actually help cancer patients live longer, according to the findings of a new study.

• Keytruda, Tecentriq Get New Bladder Cancer Restrictions From FDA

  June 25, 2018

  Irvin Jackson

  The FDA announced new bladder cancer restrictions on the use of Keytruda and Tecentriq, following indications that they could lower survival rates for some patients.

• Keytruda, Tecentriq Side Effects May Decrease Survival Chances In Some Patients: FDA

  May 21, 2018

  Irvin Jackson

  An FDA warning indicates that Keytruda and Tecentriq may decrease the risk of survival in certain metastatic urothelial cancer patients.

• Yervoy, Keytruda Linked To Muscoskeletal Immune-Related Adverse Event Problems: Study

  March 26, 2018

  Irvin Jackson

  The side effects of Yervoy, Keytruda and other similar cancer drugs may increase the risk of musculoskeletal problems, according to the findings of a new study.